SARS-CoV-2 BA.2 variant spike glycoprotein (Spike protein (S protein), but for variant specificity, often referred to as BA.2 spike.)

The SARS-CoV-2 BA.2 variant spike glycoprotein is the trimeric viral envelope protein critical for SARS-CoV-2 infection. It mediates virus entry by binding to human angiotensin-converting enzyme 2 (ACE2) via its receptor-binding domain (RBD) and initiates membrane fusion through large conformational changes following proteolytic cleavage[1][5][6]. The BA.2 variant is defined by specific mutations in its spike protein, affecting affinity for ACE2, susceptibility to neutralizing antibodies, and immune escape potential[7]. The spike is extensively glycosylated, which shields epitopes from immune surveillance[6][2]. Therapeutic strategies and vaccines for COVID-19 chiefly target this glycoprotein[5][3][4]. The spike’s conformational dynamics, sequence variation (especially across variants such as BA.2), and antigenicity remain at the forefront of COVID-19 research and drug development[4][7].

Other names

SARS-CoV-2 spike proteinSpike protein (S protein)S glycoproteinS protein BA.2SARS-CoV-2 S (BA.2)

Neutralizing antibodies bind spike’s receptor-binding domain to block ACE2 interaction and cell entry\nProtease inhibitors block spike cleavage needed for membrane fusion\nVaccines elicit antibodies and T cell responses against spike’s epitopes